Helpful Resources

For patients, families & friends

Find your local chapter

Information center

Glossary
Know the terms, understand your care

ClinicalTrials.gov
A service of the U.S. National Institute of Health

Home > About ALF > Media Center

HEAT Study and ThermoDox® in Hepatocellular Carcinoma

Celsion Corporation is an oncology drug development company which develops targeted chemotherapeutic treatments based on a unique heat-activated liposomal technology. Celsion is currently enrolling patients in a global Phase III clinical trial – the HEAT Study – which is designed to demonstrate the safety and efficacy of ThermoDox® in hepatocellular carcinoma (HCC) patients.

The HEAT study involves an investigational anti-cancer drug, called ThermoDox®, used in combination with an approved medical device for radiofrequency ablation (RFA) in the liver.

The study will be the largest investigation of RFA in HCC and will involve approximately 600 patients in over 40 research institutions in seven countries and regions.

ThermoDox is designed as a heat-activated liposomal technology that is administered intravenously. When used in combination with RFA to ablate tumors high concentrations of doxorubicin is released directly to the tumor and the surrounding liver tissue. The primary endpoint of the trial is progression-free survival. Details regarding the HEAT Study can be found here.

For more information, contact:
mmasotti@celsion.com
443-259-4894

Page updated: January 27th, 2009